Bibbins-Domingo is a professor of medicine, epidemiology, and biostatistics at the University of California, San Francisco.Bibbins-Domingo was appointed to the position by the director of the Agency for Healthcare Research and Quality.Bibbins-Domingo’s research has focused on the epidemiology of cardiovascular disease; racial, ethnic and income disparities in heath; and clinical and public health interventions aimed at chronic disease prevention.Her scientific contributions have been recognized through her election to the National Academy of Medicine, the American Society for Clinical Investigation, and the Association of American Physicians.
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
To update Wikipedia with this information, visit the page for the subject above.
the University of California, San Francisco
Now, for the first time, an expert panel is recommending aspirin to prevent heart attacks and colorectal cancer. The guideline for those at high risk of the disease, published Monday in a draft report from the U.S. Preventive Services Task Force, is the first time a major American medical organization has issued a broad recommendation to take aspirin to prevent a form of cancer. In its latest report, the task force found that taking low-dose aspirin can help prevent heart attacks, stroke and colorectal cancer, and that the benefits outweighed the risks in adults ages 50 to 69 who are at high risk for heart disease. Dr. Kirsten Bibbins-Domingo, the task force's vice chairwoman, said the benefits of aspirin therapy were strongest for people who had a history of heart attack. The challenge is weighing the risks and benefits of daily aspirin for healthy adults "who have no other signs and symptoms but have multiple risk factors that put them at risk" for cardiovascular disease, she said.
For women in their 40s, breast cancer screening every two years can also be effective but the decision to start screening should be an individual one, taking into account a woman's health history, preferences, and how she values the potential benefits and harms, the U.S. Preventive Services Task Force said. Women in their 40s who have a mother, sister, or daughter with breast cancer may benefit more than average-risk women by beginning screening before age 50, it said. "Our findings support a range of choices available to women -- from beginning regular mammograms in their 40s, to waiting until age 50 to begin screening, when the likelihood of benefit is greater," said the Task Force's Vice Chair Kirsten Bibbins-Domingo. For women age 75 and older, the Task Force said it's unable to make a recommendation as none of the studies of breast cancer screening included women in this age group.
A government panel of experts released updated guidelines today spelling out who should be taking a daily low-dose aspirin for heart health, which also offers the added benefit of protection against colorectal cancer. Those who would benefit from the regimen, according to the U.S. Preventive Services Task Force, must meet a strict list of criteria -- including a high risk of heart disease and a low risk of bleeding side effects. Specifically, the group recommends that adults 50 to 59 years old who have a 10 percent or greater 10-year cardiovascular disease risk, are not at an increased risk for bleeding, and have a life expectancy of at least 10 years take a daily low-dose aspirin to prevent heart attack, stroke, and colorectal cancer. "As with any drug, patients and their doctors must balance the benefits and risks of taking aspirin," Dr. Kirsten Bibbins-Domingo, chair of the task force and professor of medicine, epidemiology and biostatistics at the University of California, San Francisco, told CBS News.
The task force continued to recommend against a blood test for prostate specific antigen in men 70 and older, concluding the potential harms of routine screening still outweigh the benefits for this age group. Since the last guidelines came out in 2012, new evidence has emerged suggesting that PSA tests may help lower the odds that tumors spread to other parts of the body or prove fatal for men aged 55 to 69, said task force chair Dr. Kirsten Bibbins-Domingo, a researcher at the University of California, San Francisco. New evidence also suggests it’s becoming more common for doctors to skip aggressive treatments like surgery or radiation for men with low-risk prostate tumors in favor of doing periodic tests to see if tumors grow, an approach known as active surveillance. “This new evidence led the task force to conclude that there is now a small net benefit to screening, although we continue to note that the balance of benefits and harms are close,” Bibbins-Domingo said by email.